Risk & Outlook

Risk factors highlighted the ongoing legal proceedings related to Philips Respironics and the DreamStation recall, which resulted in a $1.1 billion settlement. China presented procurement pressure and cost inflation, leading to expectations of lower Q3 comparable sales growth and an adjusted EBITA margin below the prior‑year level. The company anticipates a meaningful Q4 step‑up supported by higher volumes, innovation‑led gross‑margin improvement, and enhanced productivity contributions.